All Articles on Vaccine
Youth under 18 eligible for COVID vaccine trial registryA registry started by KPWHRI last year has sped up studies needed to protect the world against the novel coronavirus.
KP biostatisticians help monitor COVID-19 vaccine safetyDr. Jennifer Nelson explains how Kaiser Permanente scientists are helping the CDC and FDA keep an eye out for rare adverse events.
NIH-Moderna COVID-19 vaccine receives FDA Emergency Use AuthorizationThe investigational vaccine that KPWHRI’s team first tested shows an efficacy rate of about 94% as research continues.
10 ways we helped chart a safer passageKPWHRI responded to the COVID-19 hurricane with actions to improve health worldwide.
The next stage in COVID-19 vaccine researchIn a Viewpoint for JAMA, KPWHRI’s Dr. Mike Jackson plans ahead to meet the challenges of continuing to evaluate new vaccines.
Janssen phase 3 COVID-19 vaccine trial to begin at KPWHRIThe institute is participating in NIAID tests of Moderna and Johnson & Johnson vaccines.
COVID-19 vaccine generates immune response in older adultsThe investigational mRNA vaccine is also well tolerated, according to trial led by Kaiser Permanente Washington researcher and others.
Land Acknowledgment
Our Seattle offices sit on the occupied land of the Duwamish and by the shared waters of the Coast Salish people, who have been here thousands of years and remain. Learn about practicing land acknowledgment.